Search research articles
Contact Us
Filters
Showing results (201-210 of 703) with videos related to
Page
of 71
Sort By:
The British Journal of Dermatology
|
July 19, 2012
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
R M Anforth, T C M P Blumetti, R F Kefford, et al.
Cancer Immunology, Immunotherapy : CII
|
June 25, 2025
Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures
S C M A Wijnen, P Dimitriadis, I L M Reijers, et al.
Ebiomedicine
|
August 31, 2024
Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors
Su Yin Lim, Yingxin Lin, Jenny H Lee, et al.
The Lancet. Oncology
|
February 20, 2025
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
Georgina V Long, Victoria Atkinson, Serigne N Lo, et al.
The Australasian Journal of Dermatology
|
February 3, 2026
Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients
Sophie Walter, Francesca Watts, Raquel Ruiz Araujo, et al.
Andrology
|
October 27, 2023
Testicular function after non-cytotoxic and immunotherapy drug treatment
David J Handelsman, Amanda Idan, Sue Sleiman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2017
Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies
Ee Siang Choong, Serigne Lo, Martin Drummond, et al.
British Journal of Cancer
|
October 7, 2016
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
Matteo S Carlino, Vito Vanella, Christina Girgis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2012
(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
Matteo S Carlino, Catherine A B Saunders, Lauren E Haydu, et al.
The American Journal of Surgical Pathology
|
October 3, 2012
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
Georgina V Long, James S Wilmott, David Capper, et al.
Page
of 71
Search research articles
Search
Showing results (201-210 of 703) with videos related to
Sort By:
Page
of 71
The British Journal of Dermatology
|
July 19, 2012
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
R M Anforth, T C M P Blumetti, R F Kefford, et al.
Cancer Immunology, Immunotherapy : CII
|
June 25, 2025
Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures
S C M A Wijnen, P Dimitriadis, I L M Reijers, et al.
Ebiomedicine
|
August 31, 2024
Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors
Su Yin Lim, Yingxin Lin, Jenny H Lee, et al.
The Lancet. Oncology
|
February 20, 2025
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
Georgina V Long, Victoria Atkinson, Serigne N Lo, et al.
The Australasian Journal of Dermatology
|
February 3, 2026
Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients
Sophie Walter, Francesca Watts, Raquel Ruiz Araujo, et al.
Andrology
|
October 27, 2023
Testicular function after non-cytotoxic and immunotherapy drug treatment
David J Handelsman, Amanda Idan, Sue Sleiman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2017
Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies
Ee Siang Choong, Serigne Lo, Martin Drummond, et al.
British Journal of Cancer
|
October 7, 2016
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
Matteo S Carlino, Vito Vanella, Christina Girgis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2012
(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
Matteo S Carlino, Catherine A B Saunders, Lauren E Haydu, et al.
The American Journal of Surgical Pathology
|
October 3, 2012
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
Georgina V Long, James S Wilmott, David Capper, et al.
Page
of 71